You are viewing an incomplete version of our website. Please click to reload the website as full version.

Aperçu des produits pour anti-BRCA2 (BRCA2) Anticorps

Full name:
anti-Breast Cancer 2, Early Onset Anticorps (BRCA2)
Chez www.anticorps-enligne.fr sont 87 Breast Cancer 2, Early Onset (BRCA2) Anticorps de 22 de différents fournisseurs disponibles. De plus, nous expédions BRCA2 Kits (25) et BRCA2 Protéines (2) et beaucoup plus de produits pour cette protéine. Un total de 117 BRCA2 produits sont actuellement listés.
Synonymes:
AI256696, AW045498, BRCA2, BRCC2, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1, GLM3, PNCA2, RAB163
afficher tous les anticorps Gène GeneID UniProt
BRCA2 12190 P97929
BRCA2 675 P51587
BRCA2 360254  

Afficher toutes les espèces

Afficher tous les synonymes

Réactivités les plus populaires pour anti-BRCA2 (BRCA2) Anticorps

Sélectionnez vos espèces et l'application

anti-Mouse (Murine) BRCA2 Anticorps:

anti-Human BRCA2 Anticorps:

anti-Rat (Rattus) BRCA2 Anticorps:

Tous anti-BRCA2 Anticorps disponible

Vous arrivez à notre recherche pré-filtrée.

anti-BRCA2 Anticorps mieux référencés

  1. Human Monoclonal BRCA2 Primary Antibody pour IHC, IHC (p) - ABIN445491 : Wu, Jiang, Thangaraju, Wu, Couch: Induction of the BRCA2 promoter by nuclear factor-kappa B. dans The Journal of biological chemistry 2000 (PubMed)
    Show all 2 references for ABIN445491

  2. Human Monoclonal BRCA2 Primary Antibody pour IHC, IHC (fro) - ABIN445493 : Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. dans Breast cancer research : BCR 2001 (PubMed)
    Show all 2 references for ABIN445493

  3. Human Polyclonal BRCA2 Primary Antibody pour IHC, ELISA - ABIN1533759 : Wooster, Bignell, Lancaster, Swift, Seal, Mangion, Collins, Gregory, Gumbs, Micklem: Identification of the breast cancer susceptibility gene BRCA2. dans Nature 1996 (PubMed)
    Show all 2 references for ABIN1533759

  4. Human Polyclonal BRCA2 Primary Antibody pour IHC, IHC (fro) - ABIN4285196 : Moeller, Yordy, Williams, Giri, Raju, Molkentine, Byers, Heymach, Story, Lee, Sturgis, Weber, Garden, Ang, Schwartz: DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. dans Clinical cancer research : an official journal of the American Association for Cancer Research 2011 (PubMed)

Plus d’anticorps contre BRCA2 partenaires d’interaction

Zebrafish Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (Montrer TP53 Anticorps) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (Montrer PALB2 Anticorps) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (Montrer PALB2 Anticorps) and Trp53 (Montrer TP53 Anticorps) heterozygosity .

  2. Merit40 (Montrer BABAM1 Anticorps) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (Montrer FANCD2 Anticorps) mutation.

  3. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  4. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  5. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (Montrer PARP1 Anticorps) inhibition.

  6. BRCA2-mediated sequestration of nuclear RAD51 (Montrer RAD51 Anticorps) serves to prevent inappropriate DNA interactions.

  7. BRCA2 directly represses the expression of IFN-related genes

  8. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  9. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

  10. Results suggest that cellular levels of Brca2 and Rad51 (Montrer RAD51 Anticorps) are mutually dependent on each other, and that low levels of these proteins provide selective pressure for reduction of p53 (Montrer TP53 Anticorps), which permits cell growth

Human Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Study suggests an increased risk of leukaemia in women with a BRCA2 mutation who receive chemotherapy for breast cancer.

  2. Structure-activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 (Montrer RAD51 Anticorps) protein-protein interaction, is reported.

  3. Data show that there are large differences in the absolute cancer risks between breast cancer 1, early onset protein (BRCA1) and breast cancer 2, early onset protein (BRCA2) mutation carriers with higher vs lower values of the polygenic risk scores (PRS).

  4. Studies indicate almost 20% of women with high-grade serous ovarian cancer are now recognized to harbour a germ line BRCA mutation, and of these, >40% might not have a family history of cancer and would not have received BRCA1 and BRCA2 testing.

  5. BRCA2 mutation is associated with pancreatic cancer.

  6. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (Montrer PALB2 Anticorps) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (Montrer PALB2 Anticorps) and Trp53 (Montrer TP53 Anticorps) heterozygosity .

  7. The Single-molecule molecular inversion probes (smMIP)-based genetic testing enables automated and reliable analysis of the coding sequences of BRCA2.

  8. the purified RAD51 (Montrer RAD51 Anticorps) G151D protein directly and significantly enhances DNA strand exchange activity in the presence of RPA (Montrer RPA1 Anticorps). In concordance with this result, co-incubation of G151D with BRCA2 resulted in a much higher level of strand-exchange activity compared to WT RAD51 (Montrer RAD51 Anticorps). Strikingly, the RAD51 (Montrer RAD51 Anticorps) G151D variant confers resistance to multiple DNA damaging agents, including ionizing radiation, mitomycin C, and doxorubicin.

  9. BRCA2 Mutations are associated with Aggressive Prostate Tumors.

  10. 22 different BRCA2 uncertain significance were detected and p.M784V in BRCA2 was the most common uncertain significance.

BRCA2 profil antigène

Antigen Summary

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) anticorps
  • breast cancer 2, early onset (brca2) anticorps
  • breast cancer 2 (Brca2) anticorps
  • breast cancer 2, early onset (Brca2) anticorps
  • AI256696 anticorps
  • AW045498 anticorps
  • BRCA2 anticorps
  • BRCC2 anticorps
  • BROVCA2 anticorps
  • FACD anticorps
  • FAD anticorps
  • FAD1 anticorps
  • FANCB anticorps
  • FANCD anticorps
  • FANCD1 anticorps
  • GLM3 anticorps
  • PNCA2 anticorps
  • RAB163 anticorps

Protein level used designations for BRCA2

breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2

GENE ID SPECIES
100064578 Equus caballus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
675 Homo sapiens
360254 Rattus norvegicus
374139 Gallus gallus
474180 Canis lupus familiaris
507069 Bos taurus
493878 Felis catus
Fournisseurs de qualité sélectionnés pour anti-BRCA2 (BRCA2) Anticorps
Avez-vous cherché autre chose?